Navigation Links
Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
Date:11/19/2007

Commences Phase I Clinical Trial of Proprietary siRNA Molecule in Acute

Renal Failure

FREMONT, Calif., Nov. 19 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced today that it has commenced systemic dosing in humans of its proprietary product candidate, AKIi-5, a siRNA compound discovered and developed by Quark for the treatment of Acute Renal Failure (ARF), also called Acute Kidney Injury (AKI). Based on publicly available information, Quark believes that this is the first human clinical trial involving the systemic delivery of siRNA.

The Phase I clinical trial is a multi-center, double-blind, placebo controlled, dose-escalation trial assessing the safety and pharmacokinetics of AKIi-5 administered intravenously as a single dose to patients undergoing major cardiac surgery. Patients will be enrolled in the trial in a number of centers in the United States, Europe and Israel. Quark expects to complete the trial in early 2008. Depending on the results of this trial, Quark expects to initiate a dose-ranging Phase II clinical trial measuring AKIi-5 clinical activity.

Daniel Zurr, Chief Executive Officer, commented, "The initiation of human dosing in our Phase I trial in ARF signifies a very important step in Quark's clinical program and marks an important milestone in the RNAi industry. For Quark, the trial serves to further validate the strength of our pipeline and our overall expertise in the RNAi arena. With AKIi-5 now in the clinic, RTP801i-14, which we licensed to Pfizer, in a Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration, AHLi-11 in IND-enabling studies and additional RNAi-based candidate drugs in pre-clinical testing, we believe Quark has one of the most robust RNAi product portfolios in the industry.

"For the RNAi industry, the trial m
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)..., Pa., Nov. 9 ARmark Authenticatio...today an alliance in the development and introduct...ntication technology that incorporates microscopic... coatings of solid oral dosage forms (SODFs) to pr...on exclusive rights to market ARmark,s micro-tags ...
(Date:11/9/2009)... Oregon, November 9 Bend Research ...nce in applying innovative pharmaceutical,technolo...ientific and,technical problems, announced today t...x Pharmaceuticals Incorporated, a global biotechno..., Through this new collaboration, Vertex will ...
(Date:11/9/2009)...ov. 9 PAREXEL Internatio... biopharmaceutical services provider, today announ...lities for early phase clinical development throug... manufactures and distributes electrocardiogram (E...XEL is using Mortara Instrument,s Surveyor Telemet...
Breaking Medicine Technology:ARmark Authentication Technologies, LLC and Colorcon, Inc. Announce Alliance 2ARmark Authentication Technologies, LLC and Colorcon, Inc. Announce Alliance 3Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 2Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 3PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 2PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 3PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 4PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 5Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results 13493 1Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results 13493 2Biologic Agents Will Drive the Systemic Lupus Erythematosus Drug Market to More Than Quadruple to Nearly 242 Billion in 2018 13490 1Biologic Agents Will Drive the Systemic Lupus Erythematosus Drug Market to More Than Quadruple to Nearly 242 Billion in 2018 13490 2BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 13488 1BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 13488 2BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 13488 3BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 13488 4
...al Meeting -, - Conference call to be hosted toda..., Conn., Nov. 3 CuraGen Corporation,(Nasdaq: CRG...ng Phase II,trial of CR011-vcMMAE, an antibody-dru...of patients with unresectable Stage III or Stage I...ator, and Professor and Chairman of,the Department...
...ented at AASLD annual meeting, Pivotal Phase III ...ose,who failed prior treatment, SAN FRANCISCO, No...day reported that a planned interim analysis of a,...gational oral hepatitis C,protease inhibitor, in c...ly increased sustained virologic response (SVR) ra...
Other Medicine Technology:CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 2CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 3CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 4CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 5CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 6CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 7Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 2Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 3Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 4Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 5Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 6Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 7Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 8Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 9Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 10
(Date:11/9/2009)...uld boost self-esteem, researchers say , ...ldren are more likely to have handwriting problems...thout autism, researchers say. , The new study ...udy participants had autism spectrum disorder, but...e for perceptual reasoning on an IQ test. , The...
(Date:11/9/2009)...ned sexual function, study says, , , ...e able to restore sexual function to rabbits with ...e lab and implanting it, a new study reports. ,...hers say the technique could one day be used to tr...ere able to show the tissue was able to integrate ...
(Date:11/9/2009)...ire-FirstCall/ - Hard To Treat Diseases (HTDS.PK) ...is, a US$41 billion international healthcare compa...e partner, Zhejiang Tianyuan Bio-Pharmaceutical Co...nd will begin a five-year, $1 billion China initia...increase its investment in its China R&D facil...
(Date:11/9/2009)... be too late when it comes to preventing or improv...Inc. (Take Off Pounds Sensibly), the nonprofit wei... (Vocus) November 9, 2009 -- Tomorrow may b...g a diabetes condition, according to TOPS Club, In...t-loss support organization., , ,Diabetes is a dis...
(Date:11/9/2009)...ghlights positive influence of sports participatio...nt, IL (Vocus) November 9, 2009 -- As people age f...t research has highlighted the importance of exerc...issues. However, a new study published in the Nove...iplinary Approach reveals that there may be signi...
Breaking Medicine News(10 mins):Health News:Handwriting Skills May Lag in Kids With Autism 2Health News:Scientists Grow New Penile Tissue in the Lab 2Health News:Scientists Grow New Penile Tissue in the Lab 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 2Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 3Health News:High Impact Sports Participation May Improve Bone Mineral Density in Mature Athletes 2
... city to live in for springtime sufferers, , ...le, Ky., is the most challenging place to live for...thma and Allergy Foundation of America,s 2009 list... with allergies. The rankings are published annual...
...ferent accents every day. Even when a speaker of a...y than we do, we are typically able to recognize t... Laboratories, University of Western Sydney, along...l, which they term "phonological constancy." , In...
...ge from $1.5 Million - $3 Million , , PRINCETON, ...ard: DSCI), a manufacturer and marketer of advance...ed a new contract to supply private label adhesive...lion for Derma Sciences. Shipments to the custome...
...ic alliance has formed in the global battle agains...rass-roots movement Susan G. Komen for the Cure gi...st Cancer Conference, co-organized by the Breast I...fit funds for the fight against breast cancer. To ...
...cognized Nationally - , , WASHINGTON, May 6 /PR...field, Ind., has been named the National Youth Adv... Kids for her leadership in the fight against toba...w.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO ) ...
...A, May 6 Physicians, Choice, a medical billing se...et, has successfully implemented InstaMed,s singl...includes both payment and clearinghouse solutions....ering new value to the revenue cycle by accelerati...
Other Medicine News:Health News:Derma Sciences Announces New Contract With Major Medical Products Supplier for Private Label Adhesive Bandages 2Health News:Derma Sciences Announces New Contract With Major Medical Products Supplier for Private Label Adhesive Bandages 3Health News:Transatlantic alliance supports breast cancer research 2Health News:Campaign for Tobacco-Free Kids Honors Emily Kile, Greenfield, IN, as National Youth Advocate of the Year 2Health News:Physicians' Choice Leverages InstaMed's Integrated Platform for Healthcare Payment & Clearinghouse Solutions 2Health News:Physicians' Choice Leverages InstaMed's Integrated Platform for Healthcare Payment & Clearinghouse Solutions 3
...gulation (ECP) is a surgical approach to glaucoma ...lized laser application. The ciliary body (which p...from the anterior or posterior segment, through th...asily and accurately identified utilizing endoscop...
Moore Hyperopic Flap Conformer, 48 Diopter
...gulation (ECP) is a surgical approach to glaucoma ...lized laser application. The ciliary body (which p...from the anterior or posterior segment, through th...asily and accurately identified utilizing endoscop...
...gulation (ECP) is a surgical approach to glaucoma ...lized laser application. The ciliary body (which p...from the anterior or posterior segment, through th...asily and accurately identified utilizing endoscop...
Medicine Products: